drugset / Trial / NCT02914886

Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)

NCT02914886

Phase 4 Completed 14 enrolled Kinderkrankenhaus auf der Bult Sanofi · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate whether a zinc-free insulin is an effective treatment option for lipoatrophy in patients with type 1 Diabetes (T1D) and insulin pump (CSII, continuous subcutaneous insulin infusion) therapy.

Timeline

Start
2016-09
Primary completion
2019-04
Completion
2019-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin glulisine Protein / enzyme biologic Subcutaneous